Business
Review of 2025
Genflow Biosciences PLC reported on its 2025 progress, highlighting advancements in its canine aging study (GF-1004) with no adverse events observed during the dosing phase and an initial efficacy readout expected in Q1 2026. The company also made strides with its MASH program (GF-1002), repositioning it for advanced fibrosis and generating preclinical data on HCC prevention, while exploring mRNA/LNP delivery. Genflow expanded into ophthalmology with a SIRT6-based gene therapy for glaucoma, targeting the USD $12-14 billion market by the early 2030s, and is advancing its sarcopenia program and ExoFastTrack initiative. Looking to 2026, Genflow plans to rationalize its pipeline, prioritize programs with strong data and partner interest, and pursue early-stage licensing to generate non-dilutive funding. Disclaimer*
About this update from Genflow Biosciences Plc
[{"type":"text","content":"\n\n08 January 2026 \n\n \nA Review of an Exciting 2025\n \n2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs.\n \nThese advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025.\n \nProgram Highlights\n \nWe've made a number of notable strides across our programs this year, including:\n\n· Dog Aging (GF-1004)\nWe made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed. No adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed. The study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers.\n \nDogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects.\n \n· MASH (GF-1002)\nOur MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC.\n \nWe are now finalizing our IND package and e...